Abbott Expects Science To “Trump” Scale; Sees Industry In “Transformation”
Executive Summary
Abbott's formula for navigating a period of "transformation" in the pharmaceutical industry includes focusing on therapeutic categories where science matters more than scale, CEO Miles White told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 3 in New York
You may also be interested in...
Novartis Applauds Medicare Rx Pilot; Overall Bill “Somewhat Negative”
Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs
Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011